Impact of Delayed-Dose Administration of USL255, Qudexy™ XR (Topiramate) Extended-Release Capsules

Impact of Delayed-Dose Administration of USL255, Qudexy™ XR (Topiramate) Extended-Release Capsules

Conference: American Academy of Neurology (AAN)
Division: Cognigen

Despite the importance of medication adherence for successful management of seizure disorders, nonadherence continues to be a significant problem in patients with epilepsy.

Use of a systems model of drug-induced liver injury (DILIsym(®)) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice.

Use of a systems model of drug-induced liver injury (DILIsym(®)) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice.

Publication: Toxicol Lett
Software: DILIsym®
Division: DILIsym Services

Acetaminophen (APAP) has been used as a probe drug to investigate drug-induced liver injury (DILI). In mice, 3'-hydroxyacetanilide (AMAP), a less-toxic isomer of APAP, has also been studied as a negative control.

From Bench to Humans: Formulation Development of a Poorly Water Soluble Drug to Mitigate Food Effect

From Bench to Humans: Formulation Development of a Poorly Water Soluble Drug to Mitigate Food Effect

Publication: AAPS PharmSciTech
Software: GastroPlus®

This study presents a formulation approach that was shown to mitigate the dramatic food effect observed for a BCS Class II drug. In vitro (dissolution), in vivo (dog), and in silico (GastroPlus®) models...

Application of Physiologically Based Absorption Modeling to Formulation Development of a Low Solubility, Low Permeability Weak Base: Mechanistic Investigation of Food Effect

Application of Physiologically Based Absorption Modeling to Formulation Development of a Low Solubility, Low Permeability Weak Base: Mechanistic Investigation of Food Effect

Publication: AAPS PharmSciTech
Software: GastroPlus®

Physiologically based pharmacokinetic (PBPK) modeling has been broadly used to facilitate drug development, hereby we developed a PBPK model to systematically investigate the...

A Case Study of In Silico Modelling of Ciprofloxacin Hydrochloride / Metallic Compound Interactions

A Case Study of In Silico Modelling of Ciprofloxacin Hydrochloride / Metallic Compound Interactions

Publication: AAPS PharmSciTech
Software: GastroPlus®

With the development of physiologically based absorption models, there is an increased scientific and regulatory interest in in silico modelling and simulation of drug-drug and drug-food interactions.

Modelling the Absorption of Metformin with Patients Post Gastric Bypass Surgery

Modelling the Absorption of Metformin with Patients Post Gastric Bypass Surgery

Publication: J Diabetes Metab
Software: GastroPlus®
Division: Simulations Plus

Gastric bypass surgery in obesity shortens the length of the small intestine, which can have a significant impact on drug absorption.

Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction

Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction

Publication: CPT Pharmacometrics Syst Pharmacol
Software: GastroPlus®

Herb-drug interaction predictions remain challenging. Physiologically based pharmacokinetic (PBPK) modeling was used to improve prediction accuracy of potential herb-drug interactions...

Computational Modeling of OATP1B1 Inhibitors

Computational Modeling of OATP1B1 Inhibitors

Conference: SOT
Software: ADMET Predictor®
Division: Simulations Plus

This poster was presented at the 2014 SOT meeting.  It describes where the OATP1b1 data originated and the cutoff value.  The model, including descriptors, is discussed.

Quantitative Modeling Uncovers a Potential Limitation in the Putative Mechanism of CCl4 Hepatotoxicity

Quantitative Modeling Uncovers a Potential Limitation in the Putative Mechanism of CCl4 Hepatotoxicity

Conference: SOT
Software: DILIsym®
Division: DILIsym Services

Drug-induced liver injury (DILI) is one of the leading causes of drug development failures and drug withdrawals. DILIsym® is being developed to identify and mitigate DILI risk through in silico…

Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness

Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness

Publication: Cancer Res

Changes to androgen signaling during prostate carcinogenesis are associated with both inhibition of cellular differentiation and promotion of malignant phenotypes.

Where top-down meets bottom-up: Combined population PK (PopPk) and PBPK approaches to evaluate the impact of food and gastric pH on the pharmacokinetics of GDC-0941

Where top-down meets bottom-up: Combined population PK (PopPk) and PBPK approaches to evaluate the impact of food and gastric pH on the pharmacokinetics of GDC-0941

Conference: ASCPT
Software: GastroPlus®
Division: Simulations Plus

The phosphoinositide 3-kinase (P13K) signaling pathway is deregulated in a wide variety of cancers. GDC-0941 is a potent and selective pan-inhibitor of class I P13K.

Diaromatic sulfur-containing ‘naphthenic’ acids in process waters

Diaromatic sulfur-containing ‘naphthenic’ acids in process waters

Publication: Water Res
Software: ADMET Predictor®

Polar organic compounds found in industrial process waters, particularly those originating from biodegraded petroleum residues, include ‘naphthenic acids’ (NA).

Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects

Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects

Publication: Pharmacokinetics
Division: Simulations Plus

Accumulating evidence indicates that selective antagonism of kappa opioid receptors may provide therapeutic benefit in the treatment of major depressive disorder, anxiety disorders, and substance use disorders.